{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:42:15Z","timestamp":1759333335936,"version":"3.40.3"},"publisher-location":"Cham","reference-count":69,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319131498"},{"type":"electronic","value":"9783319131504"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-13150-4_12","type":"book-chapter","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T02:05:53Z","timestamp":1423188353000},"page":"289-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Management of Peripheral T-Cell Lymphomas"],"prefix":"10.1007","author":[{"given":"M.","family":"Gooptu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,7]]},"reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.23536","volume":"88","author":"JO Armitage","year":"2013","unstructured":"Armitage JO (2013) The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 88:910\u2013918","journal-title":"Am J Hematol"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"KJ Savage","year":"2007","unstructured":"Savage KJ (2007) Peripheral T-cell lymphomas. Blood Rev 21:201\u2013216","journal-title":"Blood Rev"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM et al (2011) Peripheral T-cell lymphoma. Blood 117:6756\u20136767","journal-title":"Blood"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma study group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019\u20135032","journal-title":"Blood"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. non-Hodgkin\u2019s lymphoma classification project. Ann Oncol Off J Eur Soc Med Oncol ESMO 9:717\u2013720","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International T-cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol Off J Am Soc Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR8","doi-asserted-by":"publisher","unstructured":"Moskowitz AJ, Lunning M, Horwitz SM (2014) How I treat the peripheral T cell lymphomas. Blood 123: 2636. doi:10.1182\/blood-2013-12-516245","DOI":"10.1182\/blood-2013-12-516245"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International peripheral T-cell Lymphoma project. Blood 117:3402\u20133408","journal-title":"Blood"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V75.2.434.434","volume":"75","author":"B Falini","year":"1990","unstructured":"Falini B et al (1990) Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 75:434\u2013444","journal-title":"Blood"},{"key":"12_CR11","first-page":"436","volume":"130","author":"LM Weiss","year":"1988","unstructured":"Weiss LM, Picker LJ, Grogan TM, Warnke RA, Sklar J (1988) Absence of clonal beta and gamma T-cell receptor gene rearrangements in a subset of peripheral T-cell lymphomas. Am J Pathol 130:436\u2013442","journal-title":"Am J Pathol"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115:1026\u20131036","journal-title":"Blood"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1136\/jcp.2008.055335","volume":"61","author":"C Agostinelli","year":"2008","unstructured":"Agostinelli C et al (2008) Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol 61:1160\u20131167","journal-title":"J Clin Pathol"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3109\/10428194.2013.776680","volume":"54","author":"F Broussais-Guillaumot","year":"2013","unstructured":"Broussais-Guillaumot F et al (2013) Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. Leuk Lymphoma 54:2392\u20132398","journal-title":"Leuk Lymphoma"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3960\/jslrt.51.29","volume":"51","author":"T Akagi","year":"2011","unstructured":"Akagi T et al (2011) Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. J Clin Exp Hematop (JCEH) 51:29\u201335","journal-title":"J Clin Exp Hematop (JCEH)"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ et al (2008) ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood 111:5496\u20135504","journal-title":"Blood"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418\u20133425","journal-title":"Blood"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091\u20132098","journal-title":"Cancer"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S et al (2008) Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol ESMO 19:958\u2013963","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A et al (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151:159\u2013166","journal-title":"Br J Haematol"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"H-T Arkenau","year":"2007","unstructured":"Arkenau H-T et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92:271\u2013272","journal-title":"Haematologica"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58:35\u201339","journal-title":"Cancer Chemother Pharmacol"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371\u2013379","journal-title":"Cancer"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3324\/haematol.10767","volume":"92","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566\u2013567","journal-title":"Haematologica"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316\u20132323","journal-title":"Blood"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","volume":"92","author":"C Binder","year":"2013","unstructured":"Binder C et al (2013) CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol 92:1521\u20131528","journal-title":"Ann Hematol"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL et al (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25:4293\u20134297","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"48","key":"12_CR29","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"1990","author":"SJ Kim","year":"2012","unstructured":"Kim SJ et al (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer Oxf Engl 1990(48):3223\u20133231","journal-title":"Eur J Cancer Oxf Engl"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000353778","volume":"131","author":"J Yin","year":"2014","unstructured":"Yin J, Wei J, Xu JH, Xiao Y, Zhang YC (2014) Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis. Acta Haematol 131:114\u2013125","journal-title":"Acta Haematol"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00277-013-1685-5","volume":"92","author":"J-S Ahn","year":"2013","unstructured":"Ahn J-S et al (2013) Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol 92:789\u2013797","journal-title":"Ann Hematol"},{"key":"12_CR32","first-page":"1272","volume":"88","author":"J Schetelig","year":"2003","unstructured":"Schetelig J et al (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272\u20131278","journal-title":"Haematologica"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E Jantunen","year":"2004","unstructured":"Jantunen E et al (2004) Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 33:405\u2013410","journal-title":"Bone Marrow Transplant"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S et al (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40:443\u2013450","journal-title":"Bone Marrow Transplant"},{"key":"12_CR35","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol 26:218\u2013224","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"D-H Yang","year":"2009","unstructured":"Yang D-H et al (2009) Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:118\u2013125","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol 27:106\u2013113","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533\u20131538","journal-title":"Leukemia"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F D\u2019 Amore","year":"2012","unstructured":"D\u2019 Amore F et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol Off J Am Soc Clin Oncol 30:3093\u20133099","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol Off J Am Soc Clin Oncol 26:2264\u20132271","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","volume":"19","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA et al (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 19:602\u2013606","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"12_CR42","doi-asserted-by":"publisher","unstructured":"Corradini P et al (2014) Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. doi:10.1038\/leu.2014.79","DOI":"10.1038\/leu.2014.79"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C et al (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol 27:3951\u20133958","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 31:3100\u20133109","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"PL Zinzani","year":"1998","unstructured":"Zinzani PL et al (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol Off J Eur Soc Med Oncol ESMO 9:1351\u20131353","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL et al (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol Off J Eur Soc Med Oncol (ESMO) 21:860\u2013863","journal-title":"Ann Oncol Off J Eur Soc Med Oncol (ESMO)"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","volume":"54","author":"Y Yao","year":"2013","unstructured":"Yao Y et al (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma 54:1194\u20131200","journal-title":"Leuk Lymphoma"},{"key":"12_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol Off J Am Soc Clin Oncol 31:104\u2013110","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y (2009) Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol 27:15s","journal-title":"J Clin Oncol"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","volume":"18","author":"MA Fanale","year":"2012","unstructured":"Fanale MA et al (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18:248\u2013255","journal-title":"Clin Cancer Res"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 30:2190\u20132196","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR52","unstructured":"Oki Y (2013) Safety and efficacy of brentuximab vedotin for treatment of relapsed or refractory mature T-\/NK-cell lymphomas. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2055\/full"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM et al (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095\u20133100","journal-title":"Blood"},{"key":"12_CR54","doi-asserted-by":"publisher","unstructured":"Gopal AK et al (2014) Brentuximab vedotin in patients aged 60\u00a0years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. doi:10.3109\/10428194.2013.876496","DOI":"10.3109\/10428194.2013.876496"},{"key":"12_CR55","unstructured":"A Phase III Study of Brentuximab Vedotin plus CHP versus CHOP Therapy for Patients with Previously Untreated CD30-Positive Peripheral T-Cell Lymphoma. Meml Sloan Kettering Cancer Cent http:\/\/www.mskcc.org\/cancer-care\/trial\/13-055"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","volume":"136","author":"NH Dang","year":"2007","unstructured":"Dang NH et al (2007) Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136:439\u2013447","journal-title":"Br J Haematol"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","volume":"54","author":"FM Foss","year":"2013","unstructured":"Foss FM et al (2013) A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma 54:1373\u20131379","journal-title":"Leuk Lymphoma"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/17425255.2011.595404","volume":"7","author":"FM Foss","year":"2011","unstructured":"Foss FM (2011) Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opin. Drug Metab. Toxicol. 7:1141\u20131152","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"12_CR59","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA et al (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol Off J Am Soc Clin Oncol 27:4357\u20134364","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR60","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol Off J Am Soc Clin Oncol 29:1182\u20131189","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/epi.12.52","volume":"4","author":"SJ Harrison","year":"2012","unstructured":"Harrison SJ et al (2012) A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(\u00ae)). Epigenomics 4:571\u2013589","journal-title":"Epigenomics"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol Off J Am Soc Clin Oncol 30:631\u2013636","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B et al (2014) Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol J Hematol Oncol 7:11","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"12_CR64","doi-asserted-by":"crossref","unstructured":"Zain JM, O\u2019Connor O, Zinzani PL, Norman A, Brown de NP (2010) Multicenter, open-label trial of PXD 101 in patients with relapsed\/refractory peripheral T-cell lymphoma. J Clin Oncol 28","DOI":"10.1200\/jco.2010.28.15_suppl.e18565"},{"key":"12_CR65","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","volume":"31","author":"OA O\u2019Connor","year":"2013","unstructured":"O\u2019Connor OA et al (2013) Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): results from the BELIEF trial. J Clin Oncol 31:8507","journal-title":"J Clin Oncol"},{"key":"12_CR66","first-page":"640","volume":"26","author":"R Kanagal-Shamanna","year":"2013","unstructured":"Kanagal-Shamanna R et al (2013) Differential expression of aurora-A kinase in T-cell lymphomas. Mod. Pathol. Off. J. US. Can. Acad. Pathol. Inc 26:640\u2013647","journal-title":"Mod. Pathol. Off. J. US. Can. Acad. Pathol. Inc"},{"key":"12_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","volume":"37","author":"W Qi","year":"2013","unstructured":"Qi W et al (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37:434\u2013439","journal-title":"Leuk Res"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","volume":"32","author":"JW Friedberg","year":"2014","unstructured":"Friedberg JW et al (2014) Phase II study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol Off J Am Soc Clin Oncol 32:44\u201350","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12_CR69","unstructured":"National Cancer Institute (2000) In Clin Internet (National Library of Medicine). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01466881"}],"container-title":["Cancer Treatment and Research","Non-Hodgkin Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-13150-4_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T20:20:29Z","timestamp":1676924429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-13150-4_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319131498","9783319131504"],"references-count":69,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-13150-4_12","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"7 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}